Sermorelin Pre-Research Checklist

Before a purchase order goes out, a sermorelin pre-research checklist should cover six things: lot-specific identity and purity documentation, the actual composition of the batch testing panel, whether certificates of analysis are publicly verifiable or gated behind a request form, your own receiving and storage controls, the written mechanics of pricing tiers and order minimums, and a list of licensing questions routed to your attorney rather than your supplier's sales rep. Everything else is negotiable. Sermorelin and every compound referenced here are research-use-only materials — not approved drugs, not for human consumption, and never described as therapeutics in your catalog copy or your internal records.

Where sermorelin sits in the research literature

Sermorelin is a synthetic fragment corresponding to the first 29 amino acids of growth hormone-releasing hormone. In the published literature it is studied as a GHRH analog — a tool compound used to probe signaling in the somatotropic axis, including pituitary receptor behavior and pulsatile secretion patterns in laboratory models. Research suggests the fragment retains the receptor-binding region of the full hormone while being considerably shorter, which is part of why it appears in mechanistic studies rather than only in formulation work.

That is the ceiling of what belongs in your product education. No outcome claims, no protocols, no implied benefit to any person. For a wholesale buyer the science matters for a narrower reason: short-chain peptides of this type are sensitive to handling, and identity confirmation is not optional because closely related sequences and truncated fragments are chemically similar enough that purity percentage alone tells you very little without an identity assay alongside it.

Buyers assessing sermorelin usually assess a family at the same time. Growth-hormone-axis research compounds tend to be evaluated as a group, and the same diligence framework applies across all of them. If a compound is not in a given supplier's current catalog, that is a sourcing fact to confirm directly rather than assume — catalogs change, and no article should be treated as a live inventory list.

Documentation to demand before the first purchase order

The single most useful question a buyer can ask is: can I see the certificate of analysis for the exact lot you would ship me? Not a representative batch. Not last year's reference document. The lot.

A usable COA shows the lot or batch identifier, the test date, the analytical methods used, the purity result with the chromatogram it came from, and an identity confirmation — typically mass spectrometry — demonstrating the molecular weight matches the expected sequence. It should also state who performed the testing, and whether that party is in-house or an independent laboratory. Both can be legitimate; what matters is that you know which one you are reading.

The warning signs are consistent across the industry. A COA with no lot number cannot be matched to anything. A flattened image with no visible chromatogram trace gives you a number without evidence. A purity figure with no stated method leaves you unable to tell whether it reflects HPLC analysis or something less rigorous. And a supplier who treats lab results as a paid add-on, or sends them only after a deposit clears, has told you where documentation sits in their priorities.

Ask one more question that buyers routinely skip: how long are results retained, and can you retrieve the COA for a lot you bought months ago? Traceability that expires the moment the order ships is not traceability. If a customer of yours ever asks what they received, you want to be able to answer from records rather than memory.

Separating a real testing program from a testing claim

"Third-party tested" is a phrase, not a program. The distinction shows up in what gets tested and how often.

Purity and identity are two different measurements. Purity, usually determined by high-performance liquid chromatography, describes what proportion of the material is the intended compound. Identity confirms that the intended compound is in fact what is there. A supplier reporting only one of the two has given you half an answer.

Beyond those, comprehensive batch panels commonly extend to contamination and stability categories — microbial content, bacterial endotoxin, heavy metals, residual solvents from synthesis, water content, and appearance or solubility checks. Ask which categories a supplier's panel actually includes, because "tested" without a panel list is unverifiable by design. Then ask about frequency: is every production lot tested, or is testing periodic with results extrapolated across lots? Periodic testing is a materially different risk profile, and it is rarely disclosed unless you ask.

Finally, ask whether results are published where anyone can check them without a login. Public verification changes the incentive structure. A supplier whose results are open to inspection by any buyer, competitor, or curious customer is accepting scrutiny it cannot selectively withhold.

A verification table you can run before you commit

Use this as the working sheet for any supplier conversation. The third column is what a weak answer sounds like in practice.

Pricing tiers, minimums, and the terms that belong in writing

Wholesale pricing mechanics are where buyers lose the most money quietly. Margins vary widely with volume, compound category, and how a program structures its tiers, so treat any specific figure you hear — from anyone — as something to verify against a written schedule rather than a benchmark.

The mechanics worth pinning down: whether tiers are calculated per SKU or across the whole order, whether tier status resets each order or accumulates over a period, whether freight is included at any tier, and what happens when a lot is backordered mid-order — does the rest ship, or does the whole order hold? Ask whether you can buy across compounds to reach a tier or whether each line item stands alone. Those two structures produce very different effective costs for a buyer stocking a broad catalog.

Ask about lot consistency on reorders as well. If your customers notice variation between shipments, you will be the one fielding it. A supplier that can tell you whether your reorder will come from the same lot, and can hand you the COA either way, is easier to build a catalog on than one who cannot.

The last piece is returns and damage. What is the policy on a vial that arrives compromised? Who documents it, within what window, and does resolution come as credit, replacement, or refund? Get the answer before you need it, not after.

Compliance questions that belong with your attorney

This section is informational and is not legal advice. Nothing here should be read as a conclusion about what your business may or may not do.

The honest framing is that the regulatory questions around research-use-only compounds are questions, not settled facts, and the answers depend on your business model, your professional licensing, and your jurisdiction. What a checklist can do is tell you which questions to bring to counsel and to the relevant state board before you commit inventory dollars.

Ask your attorney: how should research-use-only materials be labeled and described in our catalog, our invoices, and our marketing? What does resale of research-use-only material require of a business structured the way ours is? Are there registration, licensing, or recordkeeping obligations that attach to our entity type or to the professional licenses held by our staff? What records should we retain about lots, suppliers, and onward sale, and for how long? And what should our written policy say about the language our own staff may use?

ing the same questions to your state board where professional licensure is involved, and revisit the answers periodically rather than treating a single opinion as permanent. Suppliers can tell you what they tested and what they shipped. They cannot tell you what your business is permitted to do, and any supplier who offers that opinion confidently has stepped outside their competence.

Receiving, storage, and internal controls before the first shipment lands

Diligence does not end at the supplier's door. Set up the receiving side first, because the first shipment is a poor time to invent a process.

Decide who inspects incoming lots and against what — packaging integrity, seal condition, label legibility, and whether the lot number on the vial matches the COA on file. Log each lot with the date received, supplier, lot ID, quantity, and the location of the corresponding COA. That log is what lets you answer a question months later without guessing.

Establish storage conditions per the supplier's stated requirements and record who is responsible for monitoring them. Keep research-use-only inventory physically and administratively separate from anything else you hold, with labeling that makes the distinction obvious to anyone who opens the cabinet. Then train staff on framing: what these materials are, how they are described, and what questions get escalated rather than answered on the spot.

One boundary to write into your own documentation: Real Peptides does not provide dosing, titration, or preparation guidance, because these are research-use-only compounds. The furthest any supplier documentation appropriately goes is stating the mass of compound contained in a vial and the concentration framework that follows from it in milligrams per milliliter. Anything past that point is not education — it is instruction, and it does not belong in a wholesale relationship.

What Real Peptides does differently

Real Peptides operates a Wholesale Partner Program built around the verification points above rather than around them. Compounds are supplied at 99%+ HPLC purity, with 7-panel batch testing applied to production lots — covering purity and identity alongside contamination and stability categories, not purity alone.

Certificates of analysis are publicly verifiable. A prospective partner can read the lab results before applying, without a fee, a sales call, or a paywall, and match them against lots — which is the practical opposite of the common industry pattern where COAs are sold separately, sent only after payment, or described but never shown. Fulfillment is US-based, with a published window of 5 to 7 days, so lead time is a stated term rather than an estimate that moves order to order.

Onboarding runs as a 3-step wholesale application: submit business details, receive review, and get access to partner pricing tiers. Pricing logic is disclosed rather than negotiated privately per buyer, which matters for the buyer who wants to model a catalog before committing capital instead of after. Competitor practices worth avoiding are the structural ones — hidden pricing, testing claims with no panel disclosure, documentation that cannot be traced to a lot — and they are avoidable by asking the questions in this checklist of every supplier you evaluate, including this one.

If your business is stocking research compounds for resale and the verification standard above matches how you want to buy, the next step is the Wholesale Partner Program application — it exists to qualify businesses, confirm tier placement, and open partner pricing before you build a catalog around it.

Buyers assessing growth-hormone-axis research compounds alongside sermorelin frequently review the Growth Factor & Tissue Signaling Research collection, where catalog items such as Tesamorelin 10mg, CJC-1295 No DAC 10mg and Ipamorelin 10mg sit, while broader catalog planning usually starts with Popular Peptides, Longevity Peptides and the Mitochondrial & Metabolic Pathway Research collection at Real Peptides.